Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Contraceptive Patch

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    564 result(s) found for: Contraceptive Patch. Displaying page 1 of 29.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-007308-27 Sponsor Protocol Number: 13082 Start Date*: 2009-06-23
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multi-center, open-label, randomized, parallel-group comparison of cycle control, bleeding pattern, lipid and carbohydrate metabolism of the transdermal contraceptive patch containing 0.55 mg ethin...
    Medical condition: Prevention of pregnancy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060346 Transdermal contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-010599-45 Sponsor Protocol Number: BAY86-5016/14287 Start Date*: 2009-06-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Single-center, open-label, uncontrolled study to investigate the effects of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestodene (material no. 80876395) on t...
    Medical condition: Healthy volunteer trial, intended indication: Prevention of pregnancy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060346 Transdermal contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004214-27 Sponsor Protocol Number: 91554 Start Date*: 2009-04-29
    Sponsor Name:Bayer Healthcare AG
    Full Title: Multi-center, open-label, uncontrolled study to investigate the efficacy and safety of the transdermal contraceptive patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene (material no. 80...
    Medical condition: The primary objective of this study is to investigate the contraceptive efficacy of the transdermal contraceptive patch (material no. 80876395).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060346 Transdermal contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007024-26 Sponsor Protocol Number: BAY 86-5016/91557 Start Date*: 2009-04-27
    Sponsor Name:Bayer Healthcare AG
    Full Title: A single-center, open-label, crossover, randomized study to investigate the impact of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestogene (material no. 8087...
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060346 Transdermal contraception LLT
    9.1 10030970 Oral contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000087-95 Sponsor Protocol Number: ATI-CL17 Start Date*: 2011-05-19
    Sponsor Name:Agile Therapeutics, Inc
    Full Title: AN OPEN-LABEL, PHASE 3 STUDY OF THE CONTRACEPTIVE EFFICACY AND SAFETY OF AGILE TRANSDERMAL CONTRACEPTIVE DELIVERY SYSTEM (TCDS) IN SEXUALLY ACTIVE WOMEN REQUESTING CONTRACEPTION
    Medical condition: Female contraceptive
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10010812 Contraceptive methods female HLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000821-31 Sponsor Protocol Number: 307969 Start Date*: 2004-11-16
    Sponsor Name:Schering AG
    Full Title: Multi-center, open, randomized, parallel group comparison of cycle control for seven cycles and endometrial safety in a subgroup for thirteen cycles of contraceptive patch SH P00331F (0.9 mg ethiny...
    Medical condition: Contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005365-11 Sponsor Protocol Number: KF5303/01 Start Date*: 2006-03-31
    Sponsor Name:Grünenthal GmbH
    Full Title: A randomised, 2-arm, parallel group study assessing efficacy and tolerability of titrated transdermal buprenorphine in patients with moderate to severe chronic non malignant pain
    Medical condition: Moderate to severe chronic pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-005003-41 Sponsor Protocol Number: 392MD/15/C Start Date*: Information not available in EudraCT
    Sponsor Name:Strakan Pharmaceuticals Ltd
    Full Title: A randomised, active control, double-blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the granisetron transdermal delivery system (GTDS) ...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic multi-day chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001198-13 Sponsor Protocol Number: 310805 Start Date*: 2008-08-19
    Sponsor Name:Bayer HealthCare AG/Bayer Schering Pharma AG
    Full Title: Multicenter, open-label, randomized, uncontrolled study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gesto...
    Medical condition: The trial will be performed in healthy female volunteers. The indended indication is female contraception.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003219-26 Sponsor Protocol Number: MR-130A-01-TD-2001 Start Date*: 2023-01-10
    Sponsor Name:Mylan Pharmaceuticals, Inc
    Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women
    Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    22.0 10042613 - Surgical and medical procedures 10073728 Hormonal contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009177-10 Sponsor Protocol Number: BAY86-5016/14348 Start Date*: 2009-04-30
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in health...
    Medical condition: The trial will be performed in healthy female volunteers. The intended indication is femal contraception.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004969-27 Sponsor Protocol Number: 69HCL17_0028 Start Date*: 2018-05-28
    Sponsor Name:Hospices Civils de Lyon
    Full Title: A multicenter randomized open-label trial comparing the efficacy and safety of Infliximab versus Cyclophosphamide in Subjects with Idiopathic Refractory Scleritis CIRIS: Cyclophosphamide vs. Infli...
    Medical condition: anterior idiopathic scleritis or anterior and posterior idiopathic scleritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10039705 Scleritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002044-26 Sponsor Protocol Number: 104438 Start Date*: 2005-07-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A randomized, double-blind, placebo-controlled, post-marketing phase III Study to evaluate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults
    Medical condition: Immunization against influenza in male and female subjects aged 18 to 64 years
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-003636-30 Sponsor Protocol Number: LMS2006 Start Date*: 2008-04-16
    Sponsor Name:Karolinska University Hospital
    Full Title: Effect of continuous versus cyclic dosing regimen of hormonal contraception on bleeding pattern, cardivascular risk marker, sexual function and satisfaction
    Medical condition: The study aims to evaluate the bleeding pattern, side-effects, cardiovascular riskmarker, sexual function and user-satisfaction when combined contraceptive hormonal methods are being administered c...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010808 Contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015059-26 Sponsor Protocol Number: 510460 Start Date*: 2010-08-19
    Sponsor Name:Actavis GmbH & Co. KG
    Full Title: Efficacy of 12 weeks oral Pentalong® on Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension Short title: CAESAR Clinical efficacy ...
    Medical condition: Woman and men suffering from heart failure NYHA II-IV and secondary pulmonary hypertension Objectives PVR improvement after a 12 week oral Pentalong® therapy in addition to standard long-term HF...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019945-24 Sponsor Protocol Number: BEB-10 Start Date*: 2010-09-24
    Sponsor Name:Birken GmbH
    Full Title: Open, Prospective, Controlled Case series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare versus Non-adhesive Wound Dressing alone in Accelerating the Epitheliali...
    Medical condition: This is an open, prospective, controlled case-series documentation to compare intra-individually the efficacy and tolerance of Sericare versus standard treatment in accelerating the epithelializati...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004492-40 Sponsor Protocol Number: COHERENT Start Date*: 2021-02-03
    Sponsor Name:Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital
    Full Title: COHERENT - The COlchicine HypERtENsion Trial
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10081425 Arterial hypertension LLT
    22.0 10047065 - Vascular disorders 10081902 Arterial stiffness PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001312-59 Sponsor Protocol Number: CRO1824 Start Date*: 2011-06-24
    Sponsor Name:Imperial College London
    Full Title: A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remoduli...
    Medical condition: Pulmonary arterial hypertension (PAH) is a rare life-threatening disease characterised by high blood pressure in the arteries to the lungs, rapidly evolving in a clinical syndrome of dyspnoea and f...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011450-18 Sponsor Protocol Number: CSLCT-NHF-09-57 Start Date*: 2009-04-24
    Sponsor Name:CSL Limited
    Full Title: A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2009/2010 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged ≥ 18 to...
    Medical condition: Prophylaxis of influenza
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022000 Influenza LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012117-21 Sponsor Protocol Number: 112682 Start Date*: 2009-09-29
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (HBV) vaccine challenge in adolesce...
    Medical condition: Antibody persistence and hepatitis B vaccine challenge in adolescents aged 12-13 years, vaccinated in infancy with three doses of GSK Biologicals’ HBV vaccine in routine practice.
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:57:21 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA